Engflag

Olfen Gel

Quick links to important sections

Olfen Gel

Olfen Gel_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olfen Gel

Property Description
Active ingredient Diclofenac Sodium (Na)
Form Gel (Topical Formulation)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose Localized relief of pain and inflammation
Origin Synthetic Phenylacetic acid derivative

Classification and Core Identity

Olfen Gel is a topical medication whose active substance is Diclofenac Sodium, a powerful compound classified pharmacologically as a Nonsteroidal Anti-inflammatory Drug (NSAID). This formulation is presented as a gel designed specifically for cutaneous application to provide localized treatment for discomfort. The active component is a synthetic Phenylacetic acid derivative, placing it within a family of compounds widely recognized for managing inflammatory processes. Topical Diclofenac formulations are used for relief from localized musculoskeletal discomfort. This action helps ease discomfort by providing localized anti-inflammatory action. Unlike medications taken orally for systemic effects, the gel form is engineered to deliver the therapeutic agent locally to the underlying tissues, optimizing the drug's concentration where it is required.

Composition and General Purpose

The primary function of Olfen Gel is to provide localized relief from discomfort by reducing swelling and pain through its concentrated anti-inflammatory action. The product is a single-ingredient preparation where the active substance, Diclofenac Sodium, is suspended within a hydro-alcoholic gel base. The core mechanism involves the active ingredient inhibiting the body's production of prostaglandins, which are key messengers responsible for triggering the sensation of pain and initiating inflammation. Diclofenac is classified as an anti-inflammatory and anti-rheumatic product for local use. The primary role of the gel is to locally combat both inflammation and associated symptoms, making it a recognized choice for situations like minor strains. The specific gel formulation is designed to offer a practical alternative to other Diclofenac forms, supporting its use for direct targeting of an affected area.

Regulatory References

  1. National Institutes of Health (NIH) confirms the efficacy of topical Diclofenac

What side effects are possible with Olfen Gel?

Possible Side Effects and Safety Information

The safety profile for Olfen Gel, which contains the Nonsteroidal Anti-inflammatory Drug (NSAID) Diclofenac Sodium, is characterized primarily by reactions at the site of application. Regulatory documents classify adverse reactions based on their frequency and the body system affected.

Frequency of Documented Effects

The majority of side effects fall under the category of Skin and Subcutaneous Tissue Disorders. These frequency classifications, based on official regulatory data, help define the safety profile:

  • Common Reactions (affecting 1 to 10 users in 100): Local manifestations such as dermatitis (including contact dermatitis), rash, pruritus (itching), and erythema (redness).
  • Rare Reactions (affecting 1 to 10 users in 10,000): Bullous dermatitis (severe blistering).
  • Very Rare Reactions (affecting less than 1 user in 10,000): Severe hypersensitivity events, including angioedema (swelling beneath the skin), asthma, and photosensitivity reactions.

Systemic Risk and Contraindications

While systemic absorption is generally low, the regulatory label notes that the risk of systemic adverse reactions (side effects typical of oral NSAIDs) cannot be excluded if the gel is applied to large skin areas and/or for prolonged periods. The gel is strictly contraindicated in individuals with a known hypersensitivity to diclofenac, aspirin, or any other NSAID. Furthermore, caution is advised for specific populations, including older adults and those with pre-existing conditions like asthma or impaired renal, cardiac, or hepatic function.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation emphasizes a distinction between topical overuse and accidental ingestion of diclofenac gel. Overdose resulting in high systemic exposure is considered unlikely from normal topical application due to low absorption.

Documented Overdose Manifestations

If the gel is inadvertently swallowed, systemic effects similar to an overdose of oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may occur. Documented manifestations include nausea, vomiting, epigastric pain, gastrointestinal bleeding, lethargy, dizziness, headache, and tinnitus. Severe, potentially life-threatening outcomes reported in official labeling include acute renal failure, seizures, and severe anaphylactic reactions.

Emergency Action Required

Regulatory authorities state that immediate action must be taken in overdose scenarios. You must contact a poison control center or emergency room at once if the medicine is accidentally swallowed or if any severe systemic symptoms, such as an anaphylactic reaction, occur. For situations where the recommended dose is significantly exceeded by topical application, the instruction is to remove the gel from the skin and wash it off with water.

No specific antidote for diclofenac overdose is known; therefore, management involves symptomatic and supportive treatment. Furthermore, elderly patients and those with existing impaired renal or hepatic function are noted in the official labeling as being at a greater risk for serious adverse events following systemic exposure.

Therapeutic Uses of Olfen Gel

What Olfen Gel Treats: Main Uses and Benefits

Olfen Gel is used to provide symptomatic relief across therapeutic domains where symptoms may interfere with daily functioning. It is relevant in contexts marked by increased discomfort or tension associated with musculoskeletal issues, providing support that helps ease the overall symptom burden. The active ingredient in Olfen Gel is applied across domains where short-term symptom management is appropriate, such as those related to localized discomfort in joints.

Easing Localized Pain, Swelling, and Stiffness

It is relevant when supportive symptom management is appropriate to address pronounced symptoms. It is commonly used in situations involving certain distressing symptoms like localized pain, swelling, and stiffness arising from conditions such as minor sprains, strains, or flare-ups of non-severe soft-tissue rheumatism.

Olfen Gel is applied across domains where additional symptomatic support is needed. It contributes to easing the overall symptom load during periods of heightened symptoms, supporting functional stability when symptoms are more noticeable.

Quick Fact: Relief for Localized Pain and Acute Stiffness

Regulatory References

  1. NIH DailyMed overview for diclofenac topical gel

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Olfen Gel — official regulatory information

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and adolescents aged 14 years and over.

Populations for whom use is not recommended (if applicable): Children younger than 14 years (safety not established; use is contraindicated in many regions).

Populations for whom use is contraindicated: Patients with known hypersensitivity to diclofenac or other NSAIDs (including aspirin sensitivity); Women in the third trimester of pregnancy; Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age-related eligibility rules: Use is established for adults and adolescents ge 14. Older adults require careful monitoring.

Condition-specific eligibility rules: Use requires caution and monitoring in patients with reduced renal or liver function, heart failure, or pre-existing gastrointestinal ulcers.

Pregnancy and lactation eligibility status (if explicitly documented): Contraindicated in the third trimester. Use is restricted in the first and second trimesters. Conditional use during lactation, with a prohibition on applying the gel to the breasts.

Eligibility-related restrictions: Application is prohibited on open wounds, damaged, or non-intact skin.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated, Restricted, and Use with Caution.

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and EMA/National SmPC documents.

Eligibility-context constraints (as defined in official documents): Systemic NSAID allergy, Late-stage pregnancy, and Skin integrity.

Resulting Eligibility Structure

Official eligibility statements:

  • The gel is contraindicated in patients with a history of NSAID-induced allergic reactions and during the third trimester of pregnancy.
  • Caution is required for use in individuals with compromised renal or hepatic function.
  • The medicine is approved for use in adults and adolescents aged 14 and over.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use the medicine by establishing absolute prohibitions for sensitive populations, such as those with NSAID allergies or in late pregnancy. Use is generally permitted for adults and adolescents 14 and older but is constrained by specific cautionary rules for individuals with pre-existing organ impairment. This structure dictates the formal eligibility requirements without addressing therapeutic uses or mechanisms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Olfen Gel (Diclofenac topical gel) as listed in government regulatory sources. Due to the low systemic absorption of the topical formulation, the risk of common drug-drug interactions is generally considered low, but official prescribing information cautions against specific combinations, primarily related to potential additive systemic effects.

Official Interaction Statements

Classification Interacting Substances or Classes
Combinations Not Recommended Oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Aspirin (acetylsalicylic acid), Other Diclofenac-containing Products
Pharmacodynamic Risks Anticoagulants (increased bleeding risk), Anti-hypertensive Agents (e.g., ACE Inhibitors, ARBs), Diuretics (potential for reduced therapeutic effect)
Exposure-Altering Agents Lithium, Digoxin (potential for increased plasma concentrations)
Topical Constraints Sunscreens, Cosmetics, Lotions, or other Topical Medications (co-application at the treatment site has not been evaluated)

Population-Specific Cautions

Regulatory documents include a caution that the combined use of Olfen Gel with ACE Inhibitors or Angiotensin Receptor Blockers (ARBs) may increase the risk of renal function deterioration in specific populations, including the elderly, volume-depleted patients, or those with existing renal impairment.

Regulatory Basis

The interaction profile primarily functions as a formal warning, applying established systemic NSAID interaction risks to the topical product when there is a potential for co-administration with other high-risk drug classes.

Mechanism of Action

The mechanism of action for the active ingredient, diclofenac, is defined by its ability to modulate chemical signaling pathways active at the site of tissue damage. This core action involves functioning as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes (both constitutive and inducible isoforms). This enzymatic blockade prevents the conversion of arachidonic acid into prostaglandins, such as PGE2, which are key lipid mediators.

Suppression of PGE2 synthesis modifies the physiological process by decreasing the local concentration of inflammatory signals, which otherwise promote vasodilation and increased microvascular permeability. This decrease in PGE2 also results in altered nociceptor excitability, as prostaglandins function as chemical sensitizers of peripheral pain receptors.

The formulation facilitates this mechanism by achieving high concentrations of diclofenac in the affected soft tissues, ensuring the localized suppression of COX enzyme activity where the mechanism is required.

Dosage and Administration Information

Olfen Gel is administered topically (to the skin) and is available in concentrations such as 1% and 2% w/w. The correct usage pattern is determined by the specific concentration and the area being treated.

Official Dosing Ranges and Frequency

Formulation Dose per Application (Typical) Frequency Maximum Duration
1% Gel (General) 2–4 grams (cherry- to walnut-sized) 3–4 times daily 14 days without review
1% Gel (Alternative) 2 g (upper) or 4 g (lower extremity) 4 times daily 21 days or as directed
2% Gel (General) 2–4 grams 2 times daily (morning and evening) 7 days without advice

The lowest effective dosage should be used for the shortest duration consistent with individual treatment goals. The maximum total daily dose for the 1% gel must not exceed 32 grams across all treated joints.

Application Technique and Procedural Rules

For proper administration, the gel must be applied thinly and rubbed gently into the affected skin. Immediately after the procedure, hands must be washed completely, unless the hands are the site being treated. The gel should only be applied to intact, non-diseased skin. The product must not be used with an airtight occlusive dressing.

Population Dosing: The usual adult dosage may be used for older adults (geriatric patients). However, for adolescents under 14 years, use is generally not recommended due to insufficient data on efficacy and safety in this age group, and may be contraindicated in some jurisdictions.

Recent Clinical Evidence

Olfen Gel: Recent Clinical Evidence

Olfen Gel, containing diclofenac diethylamine (often referred to as diclofenac), is a topical non-steroidal anti-inflammatory drug (NSAID) primarily studied for localized pain and inflammation. Clinical research focuses on evaluating the drug's role in managing specific acute and chronic conditions.

Studies on Acute Musculoskeletal Conditions

Randomized, controlled trials (RCTs) have assessed the effectiveness of topical diclofenac formulations in acute conditions, such as mild-to-moderate pain related to sprains, strains, and contusions. These studies typically compare the topical application of the gel against a placebo gel. Key findings indicate that the application may be associated with a statistically significant reduction in pain scores and improved functional recovery compared to placebo over a one- to two-week treatment period.

Evidence in Chronic Joint Pain

Research has also explored the use of the topical gel in managing localized chronic pain, particularly in conditions like osteoarthritis (OA) of the knee and hand. Data from several trials suggest that the daily application of the gel may contribute to an improvement in patient-reported outcomes, including a decrease in joint stiffness and an increase in physical function over several weeks of treatment, compared to control groups.

Safety and Systemic Exposure

Topical application is designed to deliver the active ingredient directly to the affected area, aiming to limit the amount absorbed into the bloodstream. Clinical studies frequently report on the systemic absorption and generally find that plasma concentrations of diclofenac are significantly lower with topical administration compared to oral administration. The most commonly reported side effects in the clinical trials are localized skin reactions at the application site, such as mild rash, redness, or itching.

Key Studies & References Diclofenac HTP 1%, gel (diclofenac sodium) Public Assessment Report (EMA/NL License)

Frequently Asked Questions (FAQ)

Common questions about Olfen Gel (FAQ)

Q: Can I use a bandage or covering on the area after applying Olfen Gel?

Official product information states that occlusive dressings (which are airtight bandages or coverings) must not be applied to the treated skin or joint area. Regulatory warnings also state that external heat should not be applied to the area following the use of the gel.

Q: Can I use Olfen Gel with other topical pain relief products like a lidocaine patch?

Official regulatory documents caution that the combined use of Olfen Gel with other topical products on the same skin area has not been specifically evaluated. This includes other topical medications, sunscreens, and cosmetics. Questions about combining topical treatments should be directed to a healthcare professional.

Q: Is Olfen Gel suitable for treating pain in the lower back?

Official regulatory documents describe the product as indicated for localized relief of pain from osteoarthritis in joints like the knees and hands. Product labeling states that the gel has not been evaluated for use on central body areas, including the spine, hip, or shoulder.

Q: What happens if I accidentally swallow Olfen Gel?

If the gel is accidentally swallowed, official instructions recommend immediately contacting a doctor or emergency medical services (such as the nearest hospital or poison control center). This ensures appropriate guidance can be given for the individual situation.

Q: How soon after application does the pain relief begin?

Clinical literature related to the formulation suggests that the hydrogel design may facilitate the delivery of the active ingredient into the affected soft tissues. The specific time it takes for an individual to experience relief is a factor that varies from person to person.

Q: If I miss a dose, should I apply a double amount next time?

Official product information advises that if a dose is missed, individuals should not apply a double quantity to make up for the forgotten dose. Instead, the next scheduled dose should be applied at the usual time to maintain the regular treatment regimen.

How should Olfen Gel be stored and disposed of?

Olfen Gel (Diclofenac Sodium topical gel) must be stored under specific environmental and temperature controls to maintain its labeled stability.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F).
Prohibited Environment Must be explicitly kept from freezing and protected from heat.
Packaging Store in the original package to ensure protection from moisture.
Child Safety Must be kept out of the reach of children.

Disposal Instructions

Unused or expired Olfen Gel must be disposed of in accordance with local regulations and specific instructions provided by healthcare professionals. The medicine should not be discarded into wastewater or standard household trash, aligning with general regulatory guidance for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Olfen Gel found in:

A-Z Index: